Review on the pharmacological activities of lactoferricin and lactoferricin analogues

Dimana Dimitrova1, Antonia Hristova1, Momchil Lambev1, Silvia Mihaylova1, Tamara Paipanova2, Stefka Valcheva-Kuzmanova3

1 TRS Assistant Pharmacist, Medical College, Medical University of Varna
2 Institute of Molecular Biology Acad. Roumen Tsanev, Bulgarian Academy of Sciences, Sofia
3 Department of Pharmacology and Clinical Pharmacology and Therapeutics, Faculty of Medicine, Medical University of Varna

ABSTRACT

INTRODUCTION: Antimicrobial peptides (AMPs) are a growing class of natural and synthetic compounds with a wide spectrum of targets including viruses, bacteria, fungi, and parasites.

AIM: The aim of the present review was to make an overview of the available literature on the pharmacological activities of these peptides, focusing on lactoferricin and lactoferricin analogues.

MATERIALS AND METHODS: To achieve this aim, information from databases, such as PubMed, Google Scholar and ResearchGate was searched and summarized.

RESULTS: Antimicrobial peptides (AMPs) are considered a promising alternative to the antibiotics used nowadays. They have drawn a special attention in the fight against infections caused by antibiotic-resistant bacterial strains. Lactoferricin is the most studied AMP derived from milk protein. Lactoferricin (Lfcin) is a fragment of the ferro-chelate complex of the bovine protein lactoferrin (Lf). The amphipathic and cationic properties of Lfcin account for its broad spectrum antimicrobial activity. Lfcin also manifests potential antiviral, immunomodulatory, antitumor and anti-inflammatory properties. Shorter analogues of Lfcins have been synthesized with a broad spectrum of activities and enhanced pharmacokinetic properties.

CONCLUSION: Lactoferricin and its analogues are a good demonstration that it is possible to design and obtain synthetic peptides with enhanced pharmacological activities.

Keywords: antimicrobial peptides, lactoferricin, lactoferricin analogues, pharmacological activities
tive to fight against infections caused by antibiotic-resistant bacterial strains (2).

In the present paper, the pharmacological activities of synthetic peptides derived from Lactoferricin (Lfcin) are summarized on the basis of information from databases, such as PubMed, Google Scholar and ResearchGate.

**Antimicrobial Peptides (AMPs)**

AMPs can be isolated from both prokaryotes (bacteria) and eukaryotes (fungi, plants, insects and animals) (3). They are oligopeptides that contain a different number of amino acids (size from 2-10 kDa) and demonstrate amphipathic properties. They usually have a positive charge (that ranges from +2 to +9) due to the abundance of the basic amino acids such as lysine (Lys) and arginine (Arg). This allows their selective binding to the negatively charged biological membranes of microorganisms (4,5). AMPs contain also other specific amino acids such as proline (Pro) (6), tryptophan (Trp) (7,8), glycine (Gly) (9,10), cysteine (Cys) (11) or histidine (His) (12).

Trp-rich AMPs (TrAMPs) are of a particular interest. The amino acid Trp has unique biochemical properties that account for the strong antimicrobial properties of TrAMPs. Representatives of TrAMPs are indolicidin, tritrpticin and Lfcin. Indolicidin possesses activity against *E. coli, S. aureus, P. aeruginosa, S. typhimurium, S. epidermidis, T. beigelii, C. albicans, S. cerevisiae, HSV* and *G. lamblia* (13). Tritrpticin is active against *E. coli, S. aureus, P. aeruginosa, K. pneumoniae, S. epidermidis, Streptococcus* group D, *P. mirabilis* and *A. fumigatus* (13).

**Lactoferricin Structure**

Lfcin is derived from milk protein. It is a 25-amino acid fragment of the ferro-chelate complex of the bovine protein lactoferrin (Lf). When Lf enters the gastrointestinal tract, it undergoes hydrolysis by the enzyme pepsin and turns into Lfcin (14). Lfcin can be found in humans (LfcinH), in cattle (LfcinB) and mice (LfcinM) (15).

Lfcin contains both hydrophobic and hydrophilic residues (16). It contains aromatic amino acids such as tryptophan (Trp) and phenylalanine (Phe), as well as some basic amino acids, such as arginine (Arg) and lysine (Lys). Lfcin contains two cysteine residues which make up an internal disulfide bridge and ensure the amphipathic properties of the peptide (Table 1) (15).

**Lactoferricin Antimicrobial Activity**

Lfcin is a more potent antimicrobial agent in comparison with Lf (15) and its antimicrobial effect is due to its cationic and amphipathic properties (17-20). Lfcin binds to negatively charged components of bacterial membranes and disrupts the membrane integrity (21). The amino acid sequence in different types of Lfcin is related to the antimicrobial activity (Table 1).

A study of Vorland et al. (15) has shown that LfcinB has the lowest minimal inhibitory concentration (MIC) and is the only Lfcin that is active against *E. coli* and *S. aureus*. LfcinB demonstrates a stronger antimicrobial activity in comparison with LfcinH and LfcinM due to its greater hydrophobicity and the higher positive charge (15).

LfcinB-derived peptide (LfB17-41) has demonstrated activity against *E. coli, S. aureus, C. albicans, C. tropicalis, C. neoformans, HCMV, HSV* (13). The synthetic bovine Lfcin analogue (LfB17-31 or LfcinB17-31) acts against *E. coli, S. aureus, B. subtilis, S. cerevisiae, P. digitatum, P. italicum, P. expansum, Alternaria spp., A. nidulans, B. cinerea, F. oxysporum* and others.

---

**Table 1. Amino acid sequences of bovine, mouse and human Lfcins. The highlighted residues (bold) present the availability of a disulfide bond between two cysteine residues in each peptide. Adapted from Vorland et al. (15)**

| Lactoferricin (Lfcin) | Amino Acid Sequence |
|-----------------------|---------------------|
| Bovine (LfcinB)       | NH2-PHE-LYS-**CYS**-ARG-ARG-TRPGLN-TRP-ARG-MET-LYS-LEUGLY-ALA-PRO-SER-ILE-THR-**CYS**-VAL-ARG-**ARG**-ALA-PHE-COOH |
| Murine (LfcinM)       | NH2-GLU-LYS-**CYS**-LEU-ARG-TRPGLN-ASN-GLU-MET-**ARG**-LYSVAL-GLY-GLY-PRO-PRO-LEU-SER-**CYS**-VAL-LYS-SER-SER-COOH |
| Human (LfcinH)        | NH2-THR-LYS-**CYS**-PHE-GLN-TRPGLN-ARG-GLN-MET-ARG-LYSVAL-ARG-GLY-GLY-PRO-PRO-VAL-SER-**CYS**-ILE-LYS-ARG-ASP-SER-COOH |
and *M. grisea*. LfcinB20-25, another synthetic bovine Lfcin analogue, has a spectrum of activity including *E. coli*, *B. subtilis*, *S. cerevisiae*, *P. digitatum*, *P. italicum*, *P. expansum*, *Alternaria spp.*, *A. nidulans*, *B. cinerea*, *F. oxysporum* and *M. grisea*. The spectra of other bovine Lfcin analogues are respectively *E. coli*, *S. aureus*, *P. aeruginosa* for LfB17-27 and *E. coli*, *S. aureus* for LfB4-14.

---

**Lactoferricin Antiviral Activity**

HSV infection is one of the most frequent viral infections in people. Its treatment started back in the 1970s with aciclovir. Research on the mechanism of action and the knowledge about the anti-HSV activity of Lf/Lfcin have been successfully applied in designing new, more specific anti-HSV agents (22). Lf competes for the heparan sulfate attachment sites in the host cells. As a result, viral entry inhibition and

---

**Table 2. Mechanisms of the immunomodulatory and anti-inflammatory effects of bovine and human Lf and Lfcin** (36)

| Peptide and Origin | Immunomodulatory Effects |
|--------------------|--------------------------|
| **Bovine lactoferrin (LfB)** | ↓LPS-induced TNF-α in osteoblasts |
|                     | ↓flagellin-induced IL-1β in osteoclasts |
|                     | ↓TNF-α, IL-6, and GM-CSF in squamous cell carcinoma cell line |
|                     | IL-6 in LPS-treated THP-1 cells |
|                     | ↑phagocytosis of BMDM, THP-1 and U937 cells, and neutrophils |
|                     | ↓oxidative stress/apoptosis in U937 cells |
|                     | ↑CD40 in RAW 264.7 cells |
|                     | ↑IL-12 in peritoneal macrophages |
|                     | ↓T-cell proliferation and secretion of IL-5 |
|                     | ↓TNF-α and IL-6 in blood of E.coli infected mice |
|                     | ↓TNF-α and IL-6 in carrageenan-induced inflammation in rat feet |
| **Bovine lactoferricin (LfcinB)** | ↓iNOS and IL-6 in nucleus pulposus cells of human intervertebral disc |
|                     | ↓IL-1β, IL-6, iNOS, TLR-2 in chondrocytes |
|                     | ↑IL-4 and IL-10 in chondrocytes |
|                     | ↑IL-10 in articular cartilage |
|                     | ↓IL-6 in LPS-stimulated THP-1 cells |
|                     | ↑thymidine uptake by mitogen-activated splenocytes |
| **Human lactoferrin (LfH)** | ↓ICAM, E-selectin and TNF-α in HUVECs |
|                     | ↑IL-8, CXCL10, IL-10 in human DCs |
|                     | ↓TNF-α in macrophages |
|                     | ↓PGE2 secretion by breast milk macrophages |
|                     | ↓IFNγ in human DCs |
|                     | ↓IL6 in LPS-stimulated THP-1 cells |
|                     | ↓inflammation in dextran sulfate model of colitis in mice |
|                     | ↓enteritis in Shigella flexneri treated rabbits |
|                     | ↓epithelial cell proliferation |
| **Human lactoferricin (LfcinH)** | ↓myeloperoxidase activity in primary human macrophages |
|                     | ↑IL-10 in primary human macrophages |
|                     | ↓TNF-α in LPS-stimulated human mononuclear cells |
|                     | ↓TNF-α in macrophages stimulated with lipid A |
suppression of the further HSV infection of the host cells occur (23-26). Lfcins display antiviral activity against other viruses, such as HPV (27) and HIV (28).

**Lactoferricin Antitumor Activity**

Lfcins display a highly selective cytotoxic effect against tumor cells. They target the membrane anionic phosphatidylserine on the cellular membrane of cancer cells and disrupt the membrane (29). Apart from this, the peptides which translocate to the cytosol, interact with the mitochondrial membrane due to its high content of negatively charged lipids. As a consequence, they disrupt the metabolism and may induce apoptosis. Apoptosis at a late stage is induced by LfcinsB by inhibition of autophagy (30). Bovine Lf and LfcinsB exert antitumor activities on human colorectal cancer cells (HT-29) (31). LfcinB induces apoptosis in human monocytic leukemia cell lines THP-1 (32). It can be attributed to the intracellular free radical production and activation of Ca^{2+}/Mg^{2+}-dependent endonucleases (33). In vivo tests have shown that bovine lactoferrin (LfB) and LfcinB suppress tumor growth and inhibit tumor metastases in mice (34). Apart from this, LfcinB has been reported to increase the sensitivity to anticancer drugs (35). This results from LfcinB-induced inhibition of glutathione S-transferase P1 isoform (GSTP1), which is overexpressed in some cancer cells and is responsible for their resistance to anticancer drugs.

**Lactoferricin Immunomodulatory and Anti-Inflammatory Activities**

Lf and Lfcin are peptides that are able to act as immunomodulators and anti-inflammatory agents as well (Table 2) (36).

The most in-depth research of the immunomodulatory effect of these peptides refers to their ability to suppress the proinflammatory response in vivo and in vitro. Lactoferrin modulates the migration, maturation and function of immune cells (37-39).

Research on human Lf (LfH) has shown the importance of this peptide as an anti-inflammatory agent. A study conducted by Haversen et al. has convincingly demonstrated the importance of LfH in reducing the IL-1β-provoked inflammatory response in mice that suffer from in acute dextran sulphate-induced colitis (40).

LfcinB is also an effective anti-inflammatory and anti-catabolic agent. It can regulate the anti-inflammatory cytokines IL-6, IL-10, IL-11 and IL-4 (36,41). Investigations of LfcinH have also shown its ability to regulate cytokines (IL-10) and to reduce the production of TNF-α in macrophages induced by bacteria (42-44).

Some applications of Lfcins on the basis of their immunomodulatory, antimicrobial, antiviral and antitumor activities are summarized in Table 3 (15).

### Table 3. Applications of Lfcins; adapted from Hao et al., 2018 (15)

| Field | Application | Target | Object |
|-------|-------------|--------|--------|
| Preclinical | Skin cancer | - | Mouse |
| | Keratitis | *Ps. aeruginosa, S. aureus* | Mouse |
| | Herpes simplex virus | HSV-2 line | Mouse |
| Veterinary | Atopic dermatitis | - | Dog |
| | Otitis externa | Bacteria and yeast | Dog |
| | Bovine mastitis | *Staphylococci, Streptococci, E. coli* | Cow |
| | Dietary supplementation | Antibiotic alternative, *E. coli* | Weaned piglet |
| Food | Spoilage | *Pseudomonas fluorescens* | Ground beef |
| | Spoilage | *Pseudomonas spp.* | Vegetable |
| | Spoilage | Penicillium digitatum | Mandarins |
| | Spoilage | Lactic acid bacteria, *Dekkera bruxellensis* | Wine |
| | Spoilage | *Pseudomonas spp., E. coli* | Cheese |
Synthesis and Antimicrobial Activity of Lactoferrin Analogues

The design of peptides with potential pharmacological and therapeutic application is based on the synthesis of a series of structurally similar substances and tracing the relationship between structure and activity in standard pharmacological tests with the help of which their clinical efficacy can be predicted.

Peptides tend to draw a greater attention as potential drugs. Nevertheless, their application is limited because of some physicochemical characteristics. Such are the relatively high molecular mass and hydrophilicity, which lead to a limited penetration through biological membranes, as well as the degradation by peptidases and instability in the bloodstream. These properties determine a low bioavailability and short plasma half-lives. Among the chemical transformations of peptides, cyclization, the incorporating of D-amino acids or non-protein amino acids are of practical significance. Thus, the modified oligopeptides easily turn into derivatives with enhanced pharmacokinetic properties.

Recently, scientists have paid a great attention to new chemical structures which have biological activities. Analogues of the natural AMPs are being synthesized by incorporating both natural and non-natural amino acid sequences in their structure. Thus, shorter and more effective AMP derivatives are obtained. There is evidence already that AMP derivatives are able to effectively destroy pathogenic microorganisms (45). Cationic AMPs bind preferentially to the negatively charged phospholipid bilayer of bacterial membranes resulting in formation of transmembrane pores and ultimately bacterial cell death (19). The lack of specific receptors makes it difficult for bacteria to develop resistance to the peptide (46). Short peptides are supposed to demonstrate higher antimicrobial activities (45,47). The most important structural requirement for the manifestation of a high antimicrobial activity of such short peptides is the content of minimum 3 amino acid residues containing the amino acids Arg and Trp. Short peptides, which do not meet the above-mentioned requirement, demonstrate a much lower activity. Lfcins are one such example. The antimicrobial activity of Lfcin analogues as modular systems has been explored. Research is being conducted to find out which molecular characteristics are important for the antimicrobial activity. Data is available for observed antibacterial activity of the 25 amino acid fragment 17-41 of the ripe protein LfB (LfcinB). In 1996, it was shown that its undecapeptide segment 20-30 (LfB20-30) has a similar antimicrobial activity to that of the 25 amino acid fragment. The antibacterial activity of LfB20-30 is enhanced by modification that substitutes all lysine amino acid residues with arginine. The activity of the homologous undecapeptide segments 17-27 from LfcinB can be improved later with the incorporation of tryptophan amino acid residues (14). Even shorter Lfcn derivatives also manifest a good antibacterial activity. The active center of LfcinB is a hexapeptide corresponding to the 20-25 fragment. The amidation of the C-terminal of this peptide influences the potentiation of its activity in relation to E. coli (Gram-negative) and S. aureus (Gram-positive) bacteria (48).

CONCLUSION

The natural antimicrobial peptides can offer a good alternative to the conventional antibiotics, which have become highly ineffective against resistant bacterial strains. Lfcins have proven to be good antimicrobial agents (in vitro). Antiviral, immunomodulatory and antitumor activities of these peptides have also been established in vitro and in vivo. There is a possibility of potentiating the antimicrobial activity through synthesizing shorter analogues of Lfcins, which are good antimicrobial agents with a proven ability to avoid developing resistance to them.

REFERENCES

1. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance; World Health Organization: Geneva, Switzerland, 2014.
2. León-Calvijo MA, Leal-Castro AL, Almanzar-Reina GA, Rosas-Pérez JE, García-Castaneda JE, Rivera-Monroy ZJ. Antibacterial activity of synthetic peptides derived from lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212. Biomed Res Int. 2015;2015:453826. doi: 10.1155/2015/453826.
3. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 2004;24(6):536-47. doi: 10.1016/j.ijantimicag.2004.09.005.
4. Hancock RE. Peptide antibiotics. Lancet. 1997;349(9049):418-22. doi: 10.1016/S0140-6736(97)08051-7.

5. Powers JP, Hancock RE. The relationship between peptide structure and antibacterial activity. Peptides. 2003;24(11):1681-91. doi: 10.1016/j.peptides.2003.08.023.

6. Krāgl G, Hoffmann R, Chatteggoo MA, Lovas S, Cudic M, Bulet P, et al. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur J Biochem. 2002;269(17):4226-37. doi: 10.1046/j.1432-1033.2002.03119.x.

7. Chan DI, Prenner EJ, Vogel HJ. Tryptophan-rich antimicrobial peptides: structures and mechanisms of action. Biochim Biophys Acta. 2006;1758(9):1184-202. doi: 10.1016/j.bbamem.2006.04.006.

8. Dong N, Ma Q, Shan A, Lv Y, Hu W, Gu Y, et al. Strand length-dependent antibacterial activity and membrane-active mechanism of arginine- and valine-rich β-hairpin-like antimicrobial peptides. Antimicrob Agents Chemother. 2012;56(6):2994-3003. doi: 10.1128/AAC.06327-11.

9. Baumann T, Kämpfer U, Schürch S, Schaller J, Largiader C, Nentwig W, et al. Antimicrobial glycine-rich peptides from the hemocytes of the spider Cupiennius salei. Cell Mol Life Sci. 2010;67(16):2787-98. doi: 10.1007/s00018-010-0364-0.

10. Ilić N, Novković M, Guida F, Xhindoli D, Benincasa M, Tossi A, et al. Selective antimicrobial activity and mode of action of adepanists, glycine-rich peptide antibiotics based on anuran antimicrobial peptide sequences. Biochim Biophys Acta. 2013;1828(3):1004-12. doi: 10.1016/j.bbamem.2012.11.017.

11. Selsted ME, Brown DM, DeLange RJ, Harwig SS, Lehrer RI. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem. 1985;260(8):4579-84.

12. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem. 1988;263(16):7472-7.

13. Rebecca LA, Nadin MS, Enzo AP, Mrinal B. Tryptophan-rich antimicrobial peptides: properties and applications. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education. Formatex Research Center; 2013. p. 1395-1405.

14. Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yashtima T, Iwatsuki K. Twenty-five years of research on bovine lactoferrin applications. Biochimie. 2009;91(1):52-7. doi: 10.1016/j.biochi.2008.05.021.

15. Vorland LH, Ulvate H, Andersen J, Haukland H, Rekdal O, Svendsen JS, et al. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis. 1998;30(5):513-7. doi: 10.1080/00365549850161557.

16. Hwang PM, Zhou N, Shan X, Arrowsmith CH, Vogel HJ. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry. 1998;37(12):4288-98. doi: 10.1021/bj972323m.

17. Chen R, Cole N, Dutta D, Kumar N, Willcox MDP. Antimicrobial activity of immobilized lactoferrin and lactoferricin. J Biomed Mater Res B Appl Biomater. 2017;105(8):2612-7. doi: 10.1002/jbmb.33804.

18. Hoek KS, Milne JM, Grieve PA, Dionysius Dam, Smith R. Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob Agents Chemother. 1997;41(1):54-9.

19. Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci. 1991;74(12):4137-42. doi: 10.3168/jds.S0022-0302(91)78608-6.

20. Saito H, Miyakawa H, Tamura Y, Shimamura S, Tomita M. Potent bactericidal activity of bovine lactoferrin hydrolysate produced by heat treatment at acidic pH. J Dairy Sci. 1991;74(11):3724-30. doi: 10.3168/jds.S0022-0302(91)78563-9.

21. Hao Y, Yang N, Teng D, Wang X, Mao R, Wang J. A review of the design and modification of lactoferricins and their derivatives. BioMetals. 2018;32(2):1-11. doi: 10.1007/s10534-018-0086-6.

22. Jenssen H. Anti herpes simplex virus activity of lactoferrin/lactoferricin – an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci. 2005;62(24):3002-13. doi: 10.1007/s00018-005-5228-7.

23. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol. 2004;74(2):262-71. doi: 10.1002/jmv.20171.
24. Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal Ø. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 2004;61(2):101-9. doi: 10.1016/j.antiviral.2003.09.001.

25. Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 2003;58(3):209-15. doi: 10.1016/s0166-3542(02)00214-0.

26. Shestakov A, Jenssen H, Nordstrom I, Eriksson K. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. Antiviral Res. 2012;93(3):340-5. doi: 10.1016/j.antiviral.2012.01.003.

27. Mistry N, Dobni P, Naslund J, Sunkari VG, Jenssen H, Evander M. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res. 2007;75(3):258-65. doi: 10.1016/j.antiviral.2007.03.012.

28. Berkhout B, van Wamel JL, Beljaars L, Meijer DK, Visser S, Floris R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and proteinderived peptides. Antiviral Res. 2002;55(2):341-55. doi: 10.1016/s0166-3542(02)00069-4.

29. Riedl S, Rinner B, Tumer S, Schaider H, Lohner K, Zweytick D. Targeting the cancer cell membrane specifically with human lactoferricin derivatives. Ann Oncol. 2011;22(suppl. 3):iii31-iii34.

30. Pan WR, Chen PW, Chen YL, Hsu HC, Lin CC, Chen WJ. Bovine lactoferricin B induces apoptosis of human gastric cancer cell line AGS by inhibition of autophagy at a late stage. J Dairy Sci. 2013;96(12):7511-20. doi: 10.3168/jds.2013-7285.

31. Jiang R, Lönnherdal B. Bovine lactoferricin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017;95(1):99-109. doi: 10.1139/bcb-2016-0094.

32. Shigeru T, Michiko Y, Yoshiko Y, Yasuko K, Tsuke K, Keiya T. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). IJC. 1980;26(2):171-6. doi:10.1002/jic.2910260208.

33. Yoo YC, Watanabe S, Koike Y, Mitobe M, Shimagaki K, Watanabe S, et al. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk proteinderived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun. 1997;237(3):624-8. doi: 10.1006/bbrc.1997.7199.

34. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimagaki K, Azuma. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res. 1997;88(2):184-90. doi: 10.1111/j.1349-7006.1997.tb00364.x.

35. Khan AR, Taneja P. Cationic peptide lactoferricin B inhibits glutathione s-transferase P1 from human placenta and breast cancer cell line MDA-MB-231 preventing anticancer drug metabolism. Int J Pharm Pharma Sci. 2015;7:238-41.

36. Malone A. Impact of species-specific lactoferricin peptides on macrophage-associated inflammatory responses. Master Thesis. Dalhousie University Halifax, Nova Scotia, 2015.

37. Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals 2004;66(1):1-7.

38. Kruzel ML, Actor JK, Radak Z, Baci A, Saavedra-Molina A, Boldogh I, et al. Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun. 2010;16(2):67-79. doi: 10.1177/1753425909105317.

39. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol. 2002;130(1):25-31. doi: 10.1046/j.1365-2249.2002.01956.x.

40. Håversen LA, Baltzer L, Dolphin G, Hanson LA, Mattsby-Baltzer I. Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand J Immunol. 2003;57(1):2-10. doi: 10.1046/j.1365-3083.2003.01162.x.

41. Yan D, Kc R, Chen D, Xiao G, Im HJ. Bovine lactoferricin-induced anti-inflammation is, in part, via up-regulation of interleukin-11 by secondary activation of STAT3 in human articular cartilage. J Biol Chem. 2013;288(44):31655-69. doi: 10.1074/jbc.M112.440420.

42. van der Does AM, Bogaards SJ, Ravensbergen B, Beekhuizen H, van Dessel JT, Nibbering PH. Antimicrobial peptide hLF1-11 directs granulocyt/macrophage colony-stimulating factor-driven mono-
cyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010;54(2):811-6. doi: 10.1128/AAC.00652-09.

43. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun. 1999;67(3):1353-8.

44. van der Does AM, Hensbergen PJ, Bogaards SJ, Cansoy M, Deelder AM, van Leeuwen HC, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol. 2012;188(10):5012-9. doi: 10.4049/jimmunol.1102777.

45. Kuppusamy R, Willcox M, Black D, Kumar N. Short cationic peptidomimetic antimicrobials. Antibiotics (Basel). 2019;8(2): pii: E44. doi:10.3390/antibiotics8020044.

46. Laverty G, Gorman SP, Gilmore BF. The potential of antimicrobial peptides as biocides. Int J Mol Sci. 2011;12(10):6566-96. doi:10.3390/ijms12106566.

47. Chaparro S, Salguero J, Baquero D, Pérez J. Effect of polyvalence on the antibacterial activity of a synthetic peptide derived from bovine lactoferrin against healthcare-associated infectious pathogens. BioMed Res Int. 2018;6:1-12. doi:10.1155/2018/5252891.

48. Sun C, Li Y, Cao S, Wang H, Jiang C, Pang S, et al. Antibacterial activity and mechanism of action of bovine lactoferricin derivatives with symmetrical amino acid sequences. Int J Mol Sci. 2018;19(10):2951. doi: 10.3390/ijms19102951.